A Phase 3 interventional study of SCD411 and Aflibercept in Wet Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration, sponsored by Sam Chun Dang Pharm. Co. Ltd.. Completed at 130 sites in 14 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Sam Chun Dang Pharm. Co. Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Macular Degeneration with a site in Korea, Republic of — 11 open to participants now, 13 under way, 5 of them phase 3. Macular Degeneration · Korea, Republic of.
Among the 67 studies in Macular Degeneration with a site in Korea, Republic of, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2020, is one of 22 in phase 3, and was the 37th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →11 of the 67 studies in Macular Degeneration with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Junyeop Lee · Sites in Korea, Republic of
Ages 50+
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 50+
Hoffmann-La Roche · Sites in Korea, Republic of, Austria, Czechia and 10 more countries
Ages 50+
SANGMYUNG innovation · Sites in Korea, Republic of
Ages 50+
4D Molecular Therapeutics · Sites in Korea, Republic of, United States, Argentina and 14 more countries
Ages 50+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 22 · Phase 4 10
First in 2006; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 576 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 81 across the 56 interventional studies, 512 across the 11 observational. Of the 50 that completed or were terminated, 20 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 67 have an industry lead sponsor. The 10 most frequent:
Sam Chun Dang Pharm. Co. Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Sam Chun Dang Pharm. Co. Ltd. has 2 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies in Macular Degeneration with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT06924021University of Wisconsin, MadisonAge-Related Macular Degeneration Benchmark Imaging Dataset (ABID) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in Macular Degeneration with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SCD411
Drug: Aflibercept
IVT (intravitreal) injection
IVT injection
Also known as: Eylea®
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts
Time frame: Baseline to Week 8
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts
Time frame: Baseline to Week 52
Percentage of Subjects With Anti-SCD411 Antibodies
Assessed by blood samples
Time frame: Baseline, Weeks 4, 8, 20, 36 and 52
| Milestone | SCD411 | Aflibercept |
|---|---|---|
| Started | 288 | 288 |
| Completed | 259 | 256 |
| Not completed | 29 | 32 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 6 | 8 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Decision by the sponsor or administrative decision for a reason other than that of an ae | 2 | 3 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Subject missed any of first 2 doses (ivt i injection of ip at day 1 or week 4) after randomization | 0 | 1 |
| Withdrew: A decrease in bcva of ≥30 letters compared with the last assessment of va | 1 | 0 |
| Withdrew: Subretinal hemorrhage involving center of fovea or, size of hemorrhage was ≥50% of total lesion area | 1 | 0 |
| Withdrew: Other | 6 | 4 |
Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts
| Letters correctly read | SCD411 | Aflibercept |
|---|---|---|
| Change From Baseline in BCVA (Best Corrected Visual Acuity) | 5.5 (4.5 to 6.5) | 5.9 (4.8 to 6.9) |
Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts
| Letters correctly read | SCD411 | Aflibercept |
|---|---|---|
| Change From Baseline in BCVA (Best Corrected Visual Acuity) | 9.0 (7.6 to 10.4) | 7.7 (6.3 to 9.1) |
Assessed by blood samples
| Percentage of participants | SCD411 |
|---|---|
| Baseline : Positive | 7.1 |
| Baseline : Negative | 92.9 |
| Week 4 : Positive | 29.4 |
| Week 4 : Negative | 70.6 |
| Week 8 : Positive | 40.0 |
| Week 8 : Negative | 60.0 |
| Week 20 : Positive | 39.6 |
| Week 20 : Negative | 60.4 |
| Week 36 : Positive | 22.9 |
| Week 36 : Negative | 77.1 |
| Week 52 : Positive | 20.2 |
| Week 52 : Negative | 79.8 |
Collected over Adverse events were assessed beginning at enrollment (date of signed informed consent) and up to 28 days after the last dose of the study drug, up to Day 365.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SCD411 | 0/287 (0%) | 32/287 (11.1%) | 128/287 (44.6%) |
| Aflibercept | 1/286 (0.3%) | 30/286 (10.5%) | 121/286 (42.3%) |
| Event | SCD411 | Aflibercept |
|---|---|---|
| Angina pectorisCardiac disorders | 0/287 | 2/286 |
| Visual acuity reducedEye disorders | 2/287 | 1/286 |
| Retinal pigment epithelial tearEye disorders | 2/287 | 0/286 |
| COVID-19Infections and infestations | 2/287 | 1/286 |
| PneumoniaInfections and infestations | 2/287 | 0/286 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 2/287 | 0/286 |
| Amaurosis fugaxEye disorders | 0/287 | 1/286 |
| Retinal haemorrhageEye disorders | 0/287 | 1/286 |
| Visual acuity reducedEye disorders | 0/287 | 1/286 |
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 0/287 | 1/286 |
| Event | SCD411 | Aflibercept |
|---|---|---|
| COVID-19Infections and infestations | 16/287 | 21/286 |
| Neovascular age-related macular degenerationEye disorders | 20/287 | 13/286 |
| Visual acuity reducedEye disorders | 11/287 | 12/286 |
| HypertensionVascular disorders | 11/287 | 4/286 |
| Back painMusculoskeletal and connective tissue disorders | 9/287 | 10/286 |
| Urinary tract infectionInfections and infestations | 10/287 | 7/286 |
| Conjunctival haemorrhageEye disorders | 8/287 | 6/286 |
| ConjunctivitisInfections and infestations | 7/287 | 2/286 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/287 | 6/286 |
| NasopharyngitisInfections and infestations | 6/287 | 1/286 |
Included all randomized subjects who received at least 1 injection of the IP. Numbers were based on planned treatment group. Two subjects met the exclusion criteria but were randomized in error; however, they did not receive any IP injection. A third subject also did not receive any IP injection. These 3 subjects were excluded from all analyses sets.
| Age, Continuous(years) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| Mean | 73.5 ± 8 | 73.6 ± 8.55 | 73.5 ± 8.27 |
| Age, Customized(Participants) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| 50 to less than 65 years | 33 | 40 | 73 |
| 65 to less than 75 years | 131 | 119 | 250 |
| Greater than or equal to 75 years | 123 | 127 | 250 |
| Sex: Female, Male(Participants) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| Female | 149 | 147 | 296 |
| Male | 138 | 139 | 277 |
| Ethnicity (NIH/OMB)(Participants) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 19 |
| Not Hispanic or Latino | 278 | 276 | 554 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 97 | 90 | 187 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 188 | 194 | 382 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| Australia | 7 | 6 | 13 |
| Bulgaria | 2 | 2 | 4 |
| Czechia | 3 | 3 | 6 |
| Hungary | 22 | 17 | 39 |
| India | 8 | 1 | 9 |
| Israel | 42 | 42 | 84 |
| Japan | 30 | 30 | 60 |
| Latvia | 10 | 13 | 23 |
| Poland | 37 | 50 | 87 |
| South Korea | 59 | 59 | 118 |
| Russia | 12 | 10 | 22 |
| Slovakia | 16 | 13 | 29 |
| Spain | 20 | 24 | 44 |
| United States | 19 | 16 | 35 |
| Weight(kilograms) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| Mean | 72.39 ± 15.244 | 72.26 ± 12.280 | 72.32 ± 14.757 |
| Height(centimeters) | SCD411 | Aflibercept | Total |
|---|---|---|---|
| Mean | 164.02 ± 9.117 | 164.64 ± 8.976 | 164.33 ± 9.045 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 130 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Sep 2022, 24 months.
Results were first posted in Oct 2023, 1 year 1 month after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sam Chun Dang Pharm. Co. Ltd.